Methods: HIV-positive participants attending HIV clinics, diagnosed by HIVST or 54 facility-based HTC as part of a community cluster-randomised trial 55 (ISRCTN02004005), were followed from initial assessment for ART until one-year 56 postinitiation. Healthcare resource use was measured, and costing studies estimated 57 total health provider costs. Participants were interviewed to establish direct non-58 medical and indirect costs over the first-year of ART. Costs were adjusted to 2014 59 US$ and INT$. Health-related quality of life was measured using EuroQol EQ-5D.
Introduction 80
There are now over 10 million Africans receiving anti-retroviral treatment (ART), the 81 majority living in Eastern and Southern Africa.
1 Despite this impressive achievement, 82 over one half of HIV-positive individuals are still in need of treatment, and over one 83 million people become infected every year.
1 Meeting HIV elimination targets set by 84 UNAIDS ("90-90-90") will require novel approaches and significant investment in 85 HIV testing and treatment services. HIV self-testing (HIVST), defined as an 86 individual performing and interpreting their own HIV test, 2 is one potential solution, 87
and its scale-up in Africa is recommended. makes it more costly for identifying those who are HIV-positive. 6 In contrast to 96 HIVST, facility HTC services are more commonly accessed by those with advanced 97 HIV disease, 4,7 with individuals needing additional medical care to manage 98 comorbidities. 8, 9 Engaging individuals early within HIV care and treatment through 99
A C C E P T E D
HIVST may yield later cost savings. Improvements in HRQoL amongst those 100 initiating ART after testing HIV-positive through facility HTC services have been 101 demonstrated; 10 this has yet to be shown for those identified through HIVST. 102
Accurate and contemporaneous understanding of these economic outcomes will be 103 essential to inform policy on scale-up. 104
105
We recruited a cohort of adults attending HIV treatment clinics in Blantyre, Malawi, 106 after they had undergone HIVST or facility-based HTC. Our primary aim was to 107 compare the economic costs incurred by health providers and patients, and to compare 108
health-related quality of life outcomes for adults diagnosed through HIVST or 109 facility-based HTC. 110
111

Methods 112
Study design and participants 113
We undertook a prospective cohort study in Blantyre, Malawi, between March 2013 114 and January 2015. We recruited HIV-positive adults identified through either HIVST 115 or facility-based HTC who were participants of a cluster-randomised trial 116 investigating health outcomes of offering HIVST (ISRCTN02004005). 4, 5 Ethical 117 approval was obtained from the College of Medicine Ethics Review Committee, 118
University of Malawi, and the University of Warwick Biomedical Research Ethics 119
Committee. All participants provided informed consent. 120
121
The cluster-randomised trial comprised a population of approximately 34,000 122 residents 4-6 where adult HIV prevalence was approximately 18%. 11 Participants in 123 control clusters had access to routine facility-based HTC, and those in intervention 124 A C C E P T E D clusters were offered HIVST through resident community counsellors in addition to 125 facility-based HTC. Participants who self-tested did not have to disclose their HIV 126 test result to community counsellors but were offered post-test counselling, advice on 127 where to seek care and a "self-referral card" for HIV clinics. HIVST 
Health-related quality of life 183
The Chichewa EuroQoL EQ-5D-3L
17 was used to measure HRQoL after each clinic 184 visit. Participants completed both the descriptive EQ-5D-3L system and the 185 accompanying visual analogue scale (VAS) . 18 Responses to the five dimensions 186 (mobility; self-care; usual activities; pain; anxiety) of the EQ-5D-3L descriptive 187 system were converted into an EQ-5D utility score using a tariff. Tariff sets have been 188 derived from national surveys of the general population, with a subset of the 243 189 health states being valued, most commonly using the time trade-off method. 18 As 190 there is no Malawian EQ-5D tariff, we used the Zimbabwean EQ-5D tariff set to 191 derive an EQ-5D utility score for each study participant at each time point. 19 The 192 VAS is similar to a thermometer, and ranges from 100 (best imaginable health state) We undertook multiple imputation using chained equations to impute missing values 206 for cost and HRQoL estimates for participants lost to follow-up. 23 Comparable to 207 previous studies, our imputation models included mode of HIV testing received, 208 baseline CD4 count, age, sex, and socio-economic variables. 24, 25 We used predictive 209 mean matching to impute missing values for cost and HRQoL outcomes as they were 210 non-normally distributed, and to ensure imputed costs were non-negative. 26 
212
We estimated the total direct health provider cost, total direct non-medical and 213 indirect cost, and total societal costs for each study participant. For direct health 214 provider costs, we first estimated total cost for clinic consultations, total costs for 215 investigations and total costs for treatments. These costs were summed to estimate 216 total direct health provider costs. Health provider costs only included the costs of 217 providing HIV and related medical care at the clinics. The total societal cost was 218 estimated by summing all direct and indirect costs. . 219
220
We estimated costs for two time periods. The first was for the ART assessment period. 221
This included all costs from first attendance to the HIV clinic, and continued until the 222 clinic had decided whether a participant was eligible for ART initiation. The second 223 was for the first year on ART, and included all costs from the first visit to be initiated 224 A C C E P T E D onto ART until the participant had been on ART for one year. We estimated mean 225 differences in these costs by mode of HIV testing using bootstrap methods with 500 226 replications to estimate bias-corrected 95% confidence intervals (CI). 27 We undertook 227 multivariable analysis to investigate the independent effects of mode of HIV testing 228 on costs. The multivariable model was adjusted for age, sex and other socio-229 demographic variables, in addition to baseline CD4 count. 8 We used generalized 230 linear models (GLM), and ran model diagnostics to determine optimal choices for 231 distributional family and link functions. For HRQoL assessments, we estimated EQ-5D utility and VAS scores immediately 234 prior to ART initiation, and for those who initiated ART, after one-year of treatment. 235
We estimated mean differences, and 95% bootstrapped CIs, in HRQoL outcomes by 236 mode of HIV testing received. In addition, we undertook multivariable analysis to 237 investigate the independent effects of mode of HIV testing and baseline CD4 count on 238 the EQ-5D utility scores. The multivariable models were additionally adjusted for age, 239 sex and other socio-demographic variables. As EQ-5D utility scores are non-normally 240 distributed, negatively skewed and truncated at 1.0, we evaluated four commonly 241 used estimators for our multivariable analyses: ordinary least squares (OLS) 242 regression, Tobit regression, Fractional logit regression, and censored least absolute 243 deviations (CLAD) regression. [29] [30] [31] We compared mean squared error (MSE) and 244 mean absolute error (MAE) statistics between observed and estimated EQ-5D utility 245 scores to determine the choice of estimator. We also undertook sensitivity analysis 246 using the UK York A1 tariff 32 to investigate the impact of using an alternative tariff to 247 determine EQ-5D utility scores. where there was a higher proportion of missing data for the HIVST group (Table 1) . 260
261
The mean total health provider costs during the assessment period for ART initiation 262
were US$22.79 for facility HTC participants, and US$19.92 for HIVST participants 263 (Table 2) . During this period, the mean health provider costs for clinic consultations 264 were US$3.33 (bootstrap 95%CI: US$2.17-US$4.50) lower for the HIVST group. 265
The mean health provider costs for drug and other medical treatments received were 266 US$0.74 (bootstrap 95%CI: US$0.33-US$1.16) lower for the HIVST group. The 267 mean health provider costs for investigations performed were not significantly 268 different between the two groups. The mean total health provider cost was US$2.87 269 (bootstrap 95%CI: US$1.01-US$4.73) lower for the HIVST group. During the 270 assessment period for ART initiation, the mean total direct non-medical and indirect 271 costs were US$3.31 for facility HTC participants, and US$2.65 for HIVST 272 participants. The mean total direct non-medical and indirect costs were not 273 significantly different between the two groups. The mean total societal cost over this 274 A C C E P T E D period was US$3.54 (bootstrap 95%CI: US$0.37-US$6.71) lower for the HIVST 275
group. 276 277
The mean total health provider costs during the first year following ART initiation 278
were US$168.65 for facility HTC participants, and US$164.66 for HIVST 279 participants (Table 3 ). There were no significant differences in mean health provider 280 costs for clinic consultations, mean health provider costs for treatments and 281 investigations, or for mean total health provider costs between the two groups. The 282 mean total direct non-medical and indirect costs during the first year following ART 283 initiation were US$10.44 for facility HTC participants, and US$12.03 for HIVST 284 participants. The mean total direct non-medical and indirect costs were not 285 significantly different between the two groups. The mean total societal costs during 286 the first year following ART initiation were US$178.46 for facility HTC participants, 287
and US$177.55 for HIVST participants. The mean total societal costs were not 288 significantly different between the two groups. 289
290
In the multivariable analysis (Table 4) , after adjusting for participants' socio-291 demographic characteristics and CD4 count on ART assessment, the mean total 292 provider cost for ART assessment was US$3.18 (95%CI: US$1.77-US$4.59) lower 293 for the HIVST group. The mean total societal cost for ART assessment was US$3.86 294 (95%CI: US$1.64-US$6.08) lower for the HIVST group. There were no significant 295 differences in mean total provider costs or mean total societal costs during the first 296 year following ART initiation between facility HTC and HIVST participants. 
A C C E P T E D 300
The HRQoL outcomes for those who were assessed for ART, immediately prior to 301 initiation and at one-year post ART initiation, and the change in HRQoL scores 302 between these time points, are summarised in Table 5 . There were no significant 303 difference in EQ-5D utility and VAS scores immediately prior to or one year post 304
ART initiation between the two groups. Participants who were initiated onto ART 305 experienced improvements in EQ-5D utility and VAS scores. For facility HTC 306 participants who started ART, EQ-5D utility scores increased by 0.129 (SE: 0.011) 307 and VAS scores increased by 9.8 (SE: 1.7). For HIVST participants who started ART, 308 EQ-5D utility scores increased by 0.139 (SE: 0.027) and VAS scores increased by 309 10.4 (SE: 4.6). There were no significant differences between the two groups with 310 regards to the change in EQ-5D utility and VAS scores after ART initiation. 311
312
In the multivariable analysis (Table 6) , the model diagnostics showed that the OLS 313 estimator performed as well or better than the other estimators (Appendix D 314 http://links.lww.com/QAI/A996). In the fully adjusted OLS model, there was no 315 significant difference in the mean EQ-5D utility score by mode of HIV testing. In the 316 fully adjusted OLS model, the mean EQ-5D utility score was 0.043 (95%CI: 0.008-317 0.079) lower in individuals whose CD4 count was 50-200 cells/ul compared to those 318 whose CD4 count was >=350 cells/ul on assessment for ART. The mean EQ-5D 319 utility score was 0.230 (95%CI: 0.163-0.296) lower in individuals whose CD4 count 320 was below 50 cells/ul compared to those whose CD4 count was >=350 cells/ul on 321 assessment for ART. 34 Health provider and societal costs were not affected by 348 modality of HIV testing prior to entering HIV care services. Malawi has followed a 349 A C C E P T E D public health approach to scaling-up its HIV treatment services with less reliance on 350 diagnostic tests for clinical assessment, and therefore the majority of individuals 351 utilise comparable levels of healthcare resources. 35 We did not find differences in 352 healthcare utilisation between the two groups. Although it is reassuring that these 353 costs were comparable, the findings highlight opportunities to explore how HIV 354 treatment should be provided as we move towards universal access to ART. for ART eligibility, and US$13 during the first year following ART initiation. The 359 majority of Malawians live on less than $2 a day.
37 Anti-retroviral therapy is provided 360 free, but those accessing care incur costs of transport or because of taking time off 361 work to attend clinics. 38 These costs can also have a negative impact on adherence to 362 therapy.
39,40 ART can be effectively provided in people's homes through community 363 distribution models. 5, 41 Further work is needed to explore the risks and benefits of 364 home provision of treatment. 365 366 HRQoL as measured by the EQ-5D has been shown to be responsive to change 367 amongst HIV-positive patients in high-income settings, 42 but few studies have used 368 this measure in sub-Saharan African settings.
10 The EQ-5D utility score provides an 369 objective assessment of HRQoL for cost-utility analysis, with the VAS scores 370 reflecting respondents' own assessments of their HRQoL. We found EQ-5D utility 371 scores to be significantly associated with an HIV-positive individual's CD4 count, 372 with improvements after initiation of ART. Participants also reported higher VAS 373 scores after ART initiation. The findings support the beneficial impact of ART on 374 A C C E P T E D both quality and quantity of life and illustrate the importance of reaching those not in 375 care before their disease advances. The mode of HIV testing had no independent 376 impact on HRQoL outcomes. 377
378
This study is not without its limitations. The numbers recruited into the study were 379 small, and many were lost to follow-up. Although we undertook multiple imputation 380 to account for this, our findings may be limited because those lost to follow-up are 381 potentially a sicker population, with poorer HRQoL, and, had they remained in care, 382 higher healthcare resource use. We were not able to include healthcare resources 383 utilized as a result of hospitalisation, as there was no routine medical record keeping 384 or linking of records between community, outpatient and inpatient services. 385
Furthermore, some of the unit costs estimated for the healthcare resource inputs, for 386 example costs of consultations with a healthcare worker, represent average costs for 387 average reported duration of consultations. These information system issues reduced 388 our ability to detect differences in economic outcomes, but are unlikely to bias our 389
findings. 390 391
A further limitation is that the EQ-5D tool only evaluates HRQoL across five health 392 dimensions and may therefore not capture all relevant aspects of HRQoL. The lack of 393 a Malawian tariff led us to use the Zimbabwean tariff to derive EQ-5D-3L utility 394 scores. However, the EQ-5D tool is widely used for health economic analyses, and it 395 is accepted practice to use tariffs from another country where none exists for the 396 country of interest provided the two populations would value health comparably. 15 A 397 final study limitation is that the recent change in ART initiation guidelines 36 means 398 Tariff) EQ-5D Utility Score (UK Tariff) 
A C C E P T E D
